May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) ...
High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with Imfinzi (durvalumab) in ...
The phase III Volga trial evaluated perioperative Imfinzi with or without Imjudo in combination with neoadjuvant enfortumab ...
High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable ...
When 75 year old Phil Neven noticed a rust coloured tinge in his urine, he initially thought it might be kidney stones. It ...
AstraZeneca announces perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in EFS and OS in MIBC in phase III VOLGA tr ...
AstraZeneca PLC AZN on Thursday said interim results from the Phase 3 VOLGA trial showed that perioperative treatment with ...
For a survival game, Subnautica 2 has quite the prominent narrative throughline to meter out your progression.
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results